Pfizer, a major pharmaceutical company in the United States, and Biontech, a German company, have granted emergency use permission to the FDA = U.S. Food and Drug Administration for vaccines corresponding to Omicron strains "BA.4" and "BA.5" in the new coronavirus mutated virus. announced that it had filed a petition.

In the United States, the FDA recommended pharmaceutical companies to develop a vaccine that will be used for booster vaccinations from autumn onwards, adding a component corresponding to the mutated virus Omicron strain to the current vaccine.



Under these circumstances, Pfizer and Biontech announced on the 22nd that they had submitted an application to the FDA for emergency use authorization for a vaccine for the Omicron strain.



The vaccine is a type called "bivalent vaccine" that contains two types of components, one corresponding to the Omicron strain "BA.4" and "BA.5" and the other corresponding to the conventional new coronavirus, and is suitable for people aged 12 and over. We applied for additional inoculation of this.



According to the company, it will begin clinical trials to confirm the safety of the vaccine this month, and will be able to ship the vaccine immediately if FDA approval is obtained.



According to the U.S. CDC = Center for Disease Control, the number of new coronavirus infections reported daily in the United States has averaged about 100,000 since the middle of this month, and about 90% in the week until the 20th of this month was BA. Estimated to have infected 5.